Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device. | MicrobiomeTrials← Back to trialsNCT04382612
Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device.
TERMINATEDNAINTERVENTIONAL
Trial Details
Start: 2020-10-02Est. Completion: 2022-11-14
Enrollment target: 42 participants Locations- Medizinische Universität Innsbruck, Universitätsklinik für Herzchirurgie, Innsbruck, Tyrol, Austria
- Kepler Universitätsklinikum GmbH, Linz, Upper Austria, Austria
- Universitätsklinik Ulm, Ulm, Baden-Wurttemberg, Germany
- Rhön Klinikum Kardiochirurgie, Bad Neustadt an der Saale, Bavaria, Germany
- Kerckhoff Klinik GmbH, Bad Nauheim, Hesse, Germany
- Schüchtermann Klinik, Bad Rothenfelde, Lower Saxony, Germany
- Universitätsklinikum Düsseldorf, Düsseldorf, North Rhine-Westphalia, Germany
- Deutsches Herzzentrum Berlin, Berlin, Germany
- St. Antonius Ziekenhuis, Nieuwegein, Utrecht, Netherlands
- Guy's and St Thomas' NHS FOUNDATION TRUST, of Royal Brompton and Harefield Hospitals, London, United Kingdom
Other microbiome trials you might be interested in
Mitral Valve ProlapseMitral Regurgitation
Mitral regurgitation (MR) is the second most frequent valvular heart disease and the second most frequent indication for…
Milan, ItalyEst. completion Jun 1, 2029
Stiff Person Syndrome
The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%…
Multiple LocationsEst. completion Jan 2028
TERMINATED
The primary purpose of this study is to examine whether remote ischemic treatment can better the 90 - day neurological o…
Hefei, ChinaCompleted Feb 28, 2026